Annemarie van der Meij - The Consciousness Library

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Journal of Psychiatric Research June 12, 2026 Juliana Lima Constantino, Tobias Stephan Freimann, Jens H van Dalfsen et al.

Oral esketamine is a potentially effective and well-tolerated treatment for treatment-resistant depression (TRD). However, around 50% of TRD individuals treated with oral esketamine do not achieve response, and this variation in response may be accounted for by interindividual differences between patients. Efforts to develop effective and personalized depression treatment strategies are...

DOI: 10.1016/j.jpsychires.2026.06.013 Full text Esketamine Major depressive disorder Treatment-resistant depression Antidepressants +1

Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis

Open Science Framework 2026 Annemarie van der Meij, Sotiris Poyiadis, Andrea Cipriani et al.

This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depressive disorder (TRD). The project is nested within an existing network meta-analysis for TRD (NMA-TRD) project, which has already been fully specified and registered: • Muit et al., BMJ Open 2022 – protocol for a systematic review and network...

DOI: 10.17605/osf.io/k5p82 Ketamine Treatment-resistant depression Major depressive disorder Protocol science +16

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Journal of psychopharmacology (Oxford, England) April 25, 2025 Jolien Ke Veraart, Sanne Y Smith-Apeldoorn, Annemarie van der Meij et al. 6 citations

Oral esketamine for patients with treatment-resistant depression (TRD) could offer certain advantages over other routes, such as intravenous or intranasal, but it has not been systematically studied in a real-world setting. Here we present results from a relatively large naturalistic study to evaluate the effectiveness, tolerability, and safety of oral esketamine in patients with TRD. One...

DOI: 10.1177/02698811251332831 Full text Treatment-resistant depression Oral esketamine Real-world effectiveness Mental health treatment +1

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.

Molecular Psychiatry September 1, 2024 Sanne Y Smith-Apeldoorn, Jolien K E Veraart, Jeanine Kamphuis et al. 23 citations

About one-third of patients with depression do not achieve adequate response to current treatment options. Although intravenous and intranasal administrations of (es)ketamine have shown antidepressant properties, their accessibility and scalability are limited. We investigated the efficacy, safety, and tolerability of generic oral esketamine in patients with treatment-resistant depression (TRD)...

DOI: 10.1038/s41380-024-02478-9 Full text Treatment-resistant depression Depression treatment Personalized medicine Esketamine therapy +1

Papers

Predicting changes in depressive symptomatology following oral esketamine treatment in treatment-resistant depression: A machine-learning approach.

Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis

Oral esketamine for patients with severe treatment-resistant depression: Effectiveness, safety, and tolerability of a six-week open-label treatment program.

Oral esketamine in patients with treatment-resistant depression: a double-blind, randomized, placebo-controlled trial with open-label extension.